A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen

Journal of Immunology

Volumn 170, Issue 10, 2003, Pages 5188-5194

  Gold, Jason S ^a   Ferrone, Cristina R ^a   Guevara Patiño, Jose A ^a   Hawkins, William G ^a   Dyall, Ruben ^a   Engelhorn, Manuel E ^a   Wolchok, Jedd D ^a,b   Lewis, Jonathan J ^a,b   Houghton, Alan N ^a,b,c  

^a Department of Obstetrics Gynecology   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DIFFERENTIATION ANTIGEN; EPITOPE; GLYCOPROTEIN GP 100; TUMOR ANTIGEN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR REJECTION; VACCINATION;

EID: 0037884716     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.10.5188     Document Type: Article

References (28)

1. Bowne, W. B., R. Srinivasan, J. D. Wolchok, W. G. Hawkins, N. E. Blachere, R. Dyall, J. J. Lewis, and A. N. Houghton. 1999. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190:1717.
2. Hawkins, W. G., J. S. Gold, R. Dyall, J. D. Wolchok, A. Hoos, W. B. Bowne, R. Srinivasan, A. N. Houghton, and J. J. Lewis. 2000. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 128:273.
3. Naftzger, C., Y. Takechi, H. Kohda, I. Hara, S. Vijayasaradhi, and A. N. Houghton. 1996. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA 93:14809.
4. Weber, L. W., W. B. Bowne, J. D. Wolchok. R. Srinivasan, J. Qin, Y. Moroi, R. Clynes, P. Song, J. J. Lewis, and A. N. Houghton. 1998. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest. 102:1258.
5. Houghton, A. N., J. S. Gold, and N. E. Blachere. 2001. Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13:134.
6. Houghton, A. N., M. Eisinger, A. P. Albino, J. G. Cairncross, and L. J. Old. 1982. Surface antigens of melanocytes and melanomas: markers of melanocyte differentiation and melanoma subsets. J. Exp. Med. 156:1755.
7. Colella, T. A., T. N. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 191:1221.
8. Hara, I., Y. Takechi, and A. N. Houghton. 1995. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J. Exp. Med. 182:1609.
9. + T lymphocytes. Proc. Natl. Acad. Sci. USA 96:2982.
10. Bloom, M. B., D. Perry-Lalley, P. F. Robbins, Y. Li, M. el-Gamil, S. A. Rosenberg, and J. C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453.
11. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277.
12. Kawakami, Y., N. Dang, X. Wang, J. Tupesis, P. F. Robbins, R. F. Wang, J. R. Wunderlich, J. R. Yannelli, and S. A. Rosenberg. 2000. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J. Immunother. 23:17.
13. Solinger, A. M., M. E. Ultee, E. Margoliash, and R. H. Schwartz. 1979. T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibility complex-linked immune response genes. J. Exp. Med. 150:830.
14. Wang, R., Y. Wang-Zhu, C. R. Gabaglia, K. Kimachi, and H. M. Grey. 1999. The stimulation of low-affinity, nontolerized clones by heteroclitic antigen analogues causes the breaking of tolerance established to an immunodominant T cell epitope. J. Exp. Med. 190:983.
15. Dyall, R., W. B. Bowne, L. W. Weber, J. LeMaoult, P. Szabo, Y. Moroi, G. Piskun, J. J. Lewis, A. N. Houghton, and J. Nikolic-Zugic. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188:1553.
16. Slansky, J. E., F. M. Rattis, L. F. Boyd, T. Fahmy, E. M. Jaffee, J. P. Schneck, D. H. Margulies, and D. M. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13:529.
17. Bakker, A. B., S. H. van der Burg, R. J. Huijbens, J. W. Drijfhout, C. J. Melief, G. J. Adema, and C. G. Figdor. 1997. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int. J. Cancer 70:302.
18. Parkhurst, M., M. Salgaller, S. Southwood, P. Robbins, A. Sette, S. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539.
19. Valmori, D., J.-F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J.-C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160:1750.
20. Thomson, T. M., F. X. Real, S. Murakami, C. Cordon-Cardo, L. J. Old, and A. N. Houghton. 1988. Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J. Invest. Dermatol. 90:459.
21. Ross, H. M., L. W. Weber, S. Wang, G. Piskun, R. Dyall, P. Song, Y. Takechi, J. Nikolic-Zugic, A. N. Houghton, and J. J. Lewis. 1997. Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin. Cancer Res. 3:2191.
22. Dyall, R., D. H. Fremont, S. C. Jameson, and J. Nikolic-Zugic. 1996. T cell receptor (TCR) recognition of MHC class I variants: intermolecular second-site reversion provides evidence for peptide/MHC conformational variation. J. Exp. Med. 184:253.
23. Houghton, A. N., S. Vijayasaradhi, B. Bouchard, C. Naftzger, I. Hara, and P. B. Chapman. 1993. Recognition of autoantigens by patients with melanoma. Ann. NY Acad. Sci. 690:59.
24. Surman, D. R., K. R. Irvine, E. P. Shulman, T. M. Allweis, S. A. Rosenberg, and N. P. Restifo. 1998. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. J. Immunol. Methods 214:51.
25. Mamalaki, C., Y. Tanaka, P. Corbella, P. Chandler, E. Simpson, and D. Kioussis. 1993. T cell deletion follows chronic antigen specific T cell activation in vivo. Int. Immunol. 5:1285.
26. Dyall, R., L. V. Vasovic, R. A. Clynes, and J. Nikolic-Zugic. 1999. Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor. Eur. J. Immunol. 29:30.
27. Bakker, A. B., M. W. Schreurs, A. J. de Boer. Y. Kawakami, S. A. Rosenberg, G. J. Adema, and C. G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005.
28. Krieg, A. M., and H. Wagner. 2000. Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol. Today 21:521.